Below are the titles of the poster which Resverlogix will be presenting at ERA-EDTA tomorrow and Saturday.  Especially wrt the second poster, I wonder how they can present this information, as the titles suggest, without being unblinded to at least the CKD data from BETonMACE?

Inhibition of BET Proteins with Apabetalone Reduces Mediators of Vascular Calcification In Vitro and in CKD Patients. Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Chris Halliday, Chris Sarsons, Stephanie Stotz, Kamyar Kalantar-Zadeh, Ravi Jahagirdar, Kenneth Lebioda, Jan O. Johansson, Norman CW Wong, Mike Sweeney, Richard Robson, Ewelina Kulikowski. Poster sessions May 25, 2018; from 9:30am to 10:45am and from 4:30pm to 5:00pm.

BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60  K. Kalantar-Zadeh, J. Johansson, E. Kulikowski, C. Halliday, K. Lebioda, M. Sweeney, N.C. Wong, S.J. Nicholls, G.G. Schwartz and K.K. Ray. Poster sessions May 26, 2018; from 9:30am to 10:45am and from 4:30pm to 5:00pm.